Stoke Therapeutics Inc Stock
Stoke Therapeutics Inc Stock
There is an upward development for Stoke Therapeutics Inc compared to yesterday, with an increase of €0.48 (1.800%).
With 18 Buy predictions and not the single Sell prediction the community is currently very high on Stoke Therapeutics Inc.
With a target price of 33 € there is a positive potential of 21.77% for Stoke Therapeutics Inc compared to the current price of 27.1 €.
So far the community has only identified positive things for Stoke Therapeutics Inc stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Stoke Therapeutics Inc in the next few years
Pros
?
S********** s********
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Stoke Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Stoke Therapeutics Inc | 1.800% | -1.311% | 9.672% | 75.974% | 0.370% | 446.371% | 23.182% |
| Personalis Inc | -1.880% | -0.866% | -10.595% | 188.924% | 78.412% | 635.924% | -18.969% |
| Immuron | -1.120% | -2.762% | -5.376% | -39.310% | 30.370% | -43.949% | -76.963% |
Comments
Stoke Therapeutics (STOK) had its "buy" rating reaffirmed by Guggenheim. They now have a $60.00 price target on the stock.
Show more
Ratings data for STOK provided by MarketBeat
Stoke Therapeutics (STOK) had its price target raised by Wedbush from $38.00 to $40.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for STOK provided by MarketBeat
Stoke Therapeutics (STOK) had its "buy" rating reaffirmed by Chardan Capital. They now have a $35.00 price target on the stock.
Show more
Ratings data for STOK provided by MarketBeat